Indication
Indolent Adult Non-Hodgkin Lymphoma
2 clinical trials
4 products
2 drugs
Clinical trial
A Phase I Study of Venetoclax + Lenalidomide + Rituximab Hyaluronidase in Relapsed or Refractory (R/R) Indolent Non-Hodgkin's Lymphoma (iNHL).Status: Recruiting, Estimated PCD: 2025-03-31
Product
VenetoclaxProduct
LenalidomideDrug
VarlilumabClinical trial
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells TherapyStatus: Active (not recruiting), Estimated PCD: 2023-01-10
Product
ObinutuzumabDrug
glofitamab